Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...

Bayer reported that ... The failure of a late-stage study on asundexian was a major setback for the company. In the past 30 days, NVO’s EPS estimate for 2025 has increased to $3.93 from $3 ...

Bayer's AI Innovation Platform (AIIP), powered by Google Cloud technology, streamlines the development of AI-driven medical imaging software. The platform provides healthcare organizations and ...

The November 2023 discontinuation of an atrial fibrillation study for asundexian (next generation Xarelto) represented a tipping point to move Bayer’s drug division to a narrow moat rating ...